Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 7, 2012; 18(13): 1525-1530
Published online Apr 7, 2012. doi: 10.3748/wjg.v18.i13.1525
Table 1 Patient characteristics and comparisons of noninvasive biochemical parameters between mild fibrosis and significant fibrosis regarding the hepatic histology of children with non-alcoholic fatty liver disease (mean ± SD)
ParametersTotal (n = 77)Mild fibrosis(stage 0-1) (n = 51)Significant fibrosis(stage 2-3) (n = 26)P value
Clinical characteristics
Gender (M:F)66:1142:924:20.316
Age (yr)12.2 ± 2.312.0 ± 2.412.7 ± 1.90.132
AC (cm)91.1 ± 10.192.1 ± 11.689.7 ± 7.80.637
Weight (kg)68.9 ± 19.368.3 ± 21.370.2 ± 15.10.448
Height (cm)155.5 ± 12.2155.1 ± 12.1156.3 ± 12.60.407
BMI (kg/m2)28.1 ± 5.127.8 ± 5.228.7 ± 5.10.425
Biochemical parameters
AST (IU/L)82.1 ± 46.677.4 ± 46.391.3 ± 46.80.063
ALT (IU/L)167.4 ± 99.1158.7 ± 95.4184.6 ± 105.60.206
ALP (IU/L)283.7 ± 110.0273.0 ± 113.8304.7 ± 101.10.185
γGT (IU/L)53.9 ± 29.151.1 ± 25.959.4 ± 34.40.410
Total bilirubin (mg/dL)0.76 ± 0.370.75 ± 0.300.77 ± 0.500.438
Albumin (g/dL)4.54 ± 0.314.54 ± 0.324.55 ± 0.301.000
PT INR1.02 ± 0.071.01 ± 0.061.03 ± 0.080.090
Total cholesterol (mg/dL)180.2 ± 32.6176.8 ± 31.2186.9 ± 34.70.139
Triglyceride (mg/dL)132.8 ± 53.6126.6 ± 52.4142.7 ± 55.00.235
LDL cholesterol (mg/dL)97.2 ± 24.993.5 ± 20.6103.1 ± 30.20.198
HDL cholesterol (mg/dL)48.1 ± 11.448.9 ± 12.246.9 ± 10.20.995
Apoprotein A1 (mg/dL)120.2 ± 15.9121.6 ± 15.7118.1 ± 16.80.543
Apoprotein B (mg/dL)83.5 ± 17.785.6 ± 17.580.0 ± 18.30.418
Fasting glucose (mg/dL)98.1 ± 34.295.4 ± 11.9103.4 ± 56.70.311
Insulin (μIU/mL)24.6 ± 14.623.2 ± 15.526.2 ± 13.50.244
HOMA-IR5.8 ± 4.36.1 ± 4.85.3 ± 3.20.586
TNF-α (pg/mL)18.2 ± 15.015.7 ± 12.321.7 ± 18.00.400
HbA1C (%)5.7 ± 1.15.5 ± 0.35.9 ± 1.60.806
Platelet (× 109/L)307.9 ± 69.2313.2 ± 71.1297.3 ± 65.40.416
Table 2 Comparison of hepatic fibrosis scoring systems between mild fibrosis and significant fibrosis regarding the hepatic histology of children with non-alcoholic fatty liver disease (mean ± SD)
Parameters and hepatic fibrosis scoresTotal (n = 77)Mild fibrosis(stage 0-1) (n = 51)Significant fibrosis(stage 2-3) (n = 26)P value
Invasive histopathologic NAFLD scores1
Steatosis (grade 0/1/2/3)0/13/36/280/7/22/220/6/14/60.085
Inflammation (grade 0/1/2/3)9/43/25/07/29/15/02/14/10/00.325
Ballooning (grade 0/1/2)27/33/1722/21/85/12/90.018
NAS4.3 ± 1.44.18 ± 1.484.46 ± 1.140.470
Noninvasive hepatic fibrosis scoring systems
AST/ALT ratio0.53 ± 0.220.52 ± 0.160.57 ± 0.310.802
AST/platelet ratio index0.71 ± 0.490.67 ± 0.540.78 ± 0.380.032
PGA index3.78 ± 1.803.85 ± 1.893.68 ± 1.700.710
Forns index-0.94 ± 1.18-1.06 ± 0.21-0.69 ± 1.090.097
FIB4 score0.27 ± 0.160.24 ± 0.120.31 ± 0.210.010
NAFLD fibrosis score-4.95 ± 1.32-5.07 ± 1.27-4.73 ± 1.410.532
Pediatric NAFLD fibrosis index7.67 ± 2.487.71 ± 2.797.61 ± 2.080.314
Table 3 Multivariate logistic regression analysis for significant hepatic fibrosis in children with non-alcoholic fatty liver disease
VariablesOR95% CIP value
Age1.3571.027-1.7930.032
ALP1.0061.000-1.0110.035